The Star Imaging IPO provides an opportunity to invest in a company specializing in diagnostic and imaging services across India. Star Imaging & Path Lab offers advanced pathology and radiology solutions aimed at delivering accurate and timely medical reports. The company operates a network of diagnostic centers equipped with modern technology to meet the growing demand for quality healthcare diagnostics. This IPO will help the company expand its capacity and upgrade infrastructure, aligning with the rising healthcare awareness and increasing need for diagnostic services in the country. The Star Imaging IPO is positioned to capitalize on the expanding diagnostics market, making it a potential growth prospect for investors.
₹5
₹142
₹142.00
Expert Opinions
The Star Imaging IPO is met with cautious optimism reflecting growing investor interest in the healthcare diagnostics sector. The company’s strengths include a strong focus on quality diagnostics, advanced imaging technology, and a growing network of centers ensuring reliability and accuracy of reports. For FY 2025, Star Imaging reported a robust Return on Equity (ROE) of 40.65%, Return on Capital Employed (ROCE) of 29.92%, and an impressive EBITDA margin of 34.22%, highlighting operational efficiency and profitability.
Challenges include intense competition in diagnostics, regulatory risks, and dependence on maintaining technological advances. From a long-term perspective, the Star Imaging IPO provides an opportunity to invest in a healthcare firm positioned well to capitalize on India’s increasing health awareness and diagnostics demand, suitable for growth-focused investors.
Investor Considerations
The Star Imaging IPO showcases solid company performance with revenue reaching ₹85.18 crore and a PAT margin of 19.10% in FY 2025, reflecting strong fundamentals. The healthcare diagnostics sector is expanding rapidly, driven by rising health awareness and increased medical infrastructure investments. The Star Imaging IPO valuation includes a Price to Book Value of 4.07 and a manageable debt-to-equity ratio of 0.69, suggesting financial stability.
Growth prospects focus on expanding diagnostic centers and adopting advanced technology to meet demand. Risk factors include increasing competition, technological changes, and regulatory challenges. Investors with long-term goals can benefit from the company’s growth potential in the healthcare diagnostics space, while short-term investors should consider market volatility and execution risks.
| Date | GMP | Trend |
|---|---|---|
| 17 Aug 2025 12.31 | ₹5 | --- |
| 15 Aug 2025 11.38 | ₹5 | Up |
| 14 Aug 2025 10.36 | ₹00 | --- |
| 13 Aug 2025 18.43 | ₹00 | --- |
| 12 Aug 2025 10.41 | ₹00 | --- |
| 11 Aug 2025 10.58 | ₹00 | --- |
| 10 Aug 2025 14.50 | ₹00 | --- |
| 09 Aug 2025 12.23 | ₹00 | --- |
| 08 Aug 2025 11.40 | ₹00 | --- |
| 07 Aug 2025 12.35 | ₹00 | --- |
| 06 Aug 2025 10.58 | ₹00 | --- |
| 05 Aug 2025 17.59 | ₹00 | --- |
FAQs
The Grey Market Premium showed poor accuracy in predicting Star Imaging & Path Lab IPO’s listing performance. With a final GMP of ₹5, it projected a premium of 3.52% over the issue price of ₹142. The stock listed at ₹142, delivering no gain (0.00%). This resulted in a prediction error of 3.52%, where the GMP incorrectly signaled a positive listing while the stock actually listed flat, reflecting poor reliability in this case.
Star Imaging IPO Current GMP is ₹5.
Star Imaging IPO Expected Returns is 3.52%.
Star Imaging IPO estimated listing price is ₹147.